DDInter1652 DDInter1127
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.
Measles virus vaccine live attenuated {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Measles virus vaccine live attenuated {u} may lead to a major life threatening interaction when taken with {v} Talazoparib
Measles virus vaccine live attenuated {u} may lead to a major life threatening interaction when taken with {v} Tositumomab
Measles virus vaccine live attenuated may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Tositumomab